Stocks Poised for Big Moves: Intel, Jazz Pharma, Century Aluminum

Summary

What if stock winners are signaling their next move through price action, not just news? Three stocks showing strong momentum alongside improving fundamentals are Intel, Jazz Pharmaceuticals, and Century Aluminum. Intel, a struggling semiconductor giant, is being re-rated as a strategic national asset with $8.9 billion in government investment to bolster domestic chip manufacturing, aiming to be America's answer to TSMC. While its foundry business still loses money, its data center and AI segment revenue grew 22% year-over-year to over $5 billion, indicating a potential turnaround, with the stock surging from $20 to $120. Jazz Pharmaceuticals, historically strong in sleep disorders, is transforming into a diversified biotech with a focus on oncology. Its revenue grew 19% to over $1 billion, and a key cancer drug, Zani- datamab, awaits FDA approval, potentially shifting its market valuation. The stock is breaking out of a decade-long base. Century Aluminum, a commodity play, is benefiting from a tight aluminum market, low inventories, tariffs, and reshoring trends. Its revenue was $649 million with strong EBITDA, and the company is involved in building the first new US aluminum smelter in decades, alongside a minority stake in a data center project. This cyclical stock has seen a decisive breakout on strong volume. While all three carry risks, their improving fundamentals and strong price action suggest significant potential.